ГоловнаArchive of numbers2014Volume 22, issue 2(79)Inluence of derivate of 3,2’-spiro-pyrrolo-2-oxindole (com-pound r-86) at dynamic of the neurodestructive processes by acute cerebral ischemia
Title of the article Inluence of derivate of 3,2’-spiro-pyrrolo-2-oxindole (com-pound r-86) at dynamic of the neurodestructive processes by acute cerebral ischemia
Authors Bagauri Оlga Vitaliivna
In the section DIAGNOSTICS AND THERAPY OF NEUROLOGICAL DISORDERS
Year 2014 Issue Volume 22, issue 2(79) Pages 22-24
Type of article Scientific article Index UDK 616-005.4:547.756 Index BBK -
Abstract In experiments on rats with model of acute disorder of encephalic cir-culation (20  minutes bilateral carotid occlusion with further reperfusion) were established that introduction of derivate of derivate of 3,2'-spiro-pyrrolo-2-oxindole (compound R-86) in dose 10 mg/kg in the treatment mode (in an hour after modeling of insult and further one time a day after every 24  hours during 21  days) comparing with intraperitoneal introduction of the citikoline (250  mg/kg) ei ciently reduces activity of the neuron specii c enolase which indicates weakening of the neurodestructive changes in the brain during therapy with investigat-ed substances. Obtained data experi-mentally prove expediency of further investigation of the mechanisms of the cytoprotector action of derivate of 3,2'-spiro-pyrrolo-2-oxindole (com-pound R-86) and further can become the basis for development of new do-mestic cerebroprotector.
Key words derivate of 3,2'-spiro-pyrrolo-2-oxindole, ischemic insult, neuron specii c enolase, cerebropro-tection
Access to full text version of the article pdf download
Bibliography 1. Bagauri O.V., Red'kin R.G., Hodakivs'kyj O.A. Screening of anti-hypoxic activity in a number of new derivate of 3,2'-spiro-pyrrolo-2-oxindole. [Skryning antygipoksychnoi' aktyvnosti v rjadu novyh pohidnyh 3,2'-spiro-pirrolo-2-oksindolu]. Visnyk farmacii' - Journal of Pharmacy, 2013. No. 2 (74). Pp. 63-65.
2. Chekman I.S., Gubskii Iu.I., Belenichev I.F. Preclinical study of the specific activity of potential neuroprotective drugs: guidelines. [Doklinicheskoe izuchenie spetsificheskoi aktivnosti po tentsial'nykh neiroprotektivnykh preparatov: metodicheskie rekomendatsii]. Kyiv, 2010. 81 p.
3. Kitaeva E.A., Saikhunov M.V., Khasanova D.R. Neuroprotective therapy in patients with hemispheric ischemic stroke. [Neiroprotektivnaia terapiia u bol'nykh s polusharnym ishemicheskim insul'tom]. Kazanskii meditsinskii zhurnal - Kazan medical journal, 2009. No. 5. Pp. 671-675.
4. Nikonov V.V., Zozulia I.S., Mironenko T.V. Acute ischemic stroke: the comparative characteristic of citicoline. [Ostryi ishemicheskii insul't: sravnitel'naia kharakteristika tsitikolinov]. Медицина неотложных состояний- Medicine of emergency, 2012. No. 3 (42). Pp. 28-32.
5. Kladova E.A., Sosnina A.V., Doronin B.M. Assessment of inflammatory mediators in ischemic stroke. [Otsenka mediatorov vospaleniia pri ishemicheskom insul'te]. Tsitokiny i vospalenie-Cytokines and inflammation, 2011. No. 4. Pp. 20-26.
6. Piskunov A.K. Biomarkers of neuroinflammation. [Biomarkery neirovospaleniia]. Neirokhimiia - Neurochemistry, 2010. Vol. 27, no. 1. Pp. 63-73.
7. Grishanova T.G., Budaev A.V., Grigor'ev E.V. Brain damage in severe injury: the importance of clinical scales and neuronal markers. [Povrezhdenie golovnogo mozga pri tiazheloi travme: znachimost' klinicheskikh shkal i neironal'nykh markerov]. Meditsina neotlozhnykh sostoianii - Medicine of emergency, 2011. No. 1-2 (32-33). Pp. 86-90.
8. Recommendations for the management of patients with ischemic stroke and transient ischemic attacks (2008). The Executive Committee of the European Stroke Organization (ESO) and ESO Author Committee. [Rekomendatsii po vedeniiu bol'nykh s ishemicheskim insul'tom i tranzitornymi ishemicheskimi atakami (2008). Ispolnitel'nyi komitet Evropeiskoi insul'tnoi organizatsii (ESO) i Avtorskii komitet ESO]. Praktychna angiologija - Practical angiology,2008. No. 4. Pp. 9-23.
9. Troshin V.D., Brovkov N.N. Emergency cardioneurology. [Neotlozhnaia kardionevrologiia]. Мoscow: Meditsinskoe informatsionnoe agentstvo Publ., 2010. 672 p.
10. Hodakivskiy O.A. Evaluation of the influence of experimental therapy with Ademol on the intensity of destructive changes in the membranes of neurons in mongolian gerbils in acute cerebral ischemia. [Otsinka vplivu eksperimentalnoyi terapiyi ademolom na intensivnist perebigu destruktivnih zmin v membranah neyroniv u mongolskih pishchanok v umovah gostroyi tserebralnoyi ishemiyi]. Visnik morfologiyi- Journal of morphology,2011. Vol. 17., no. 1. Pp. 62-65.
11. Hodakivskiy O.A., Chereshnyuk I.L. Research of influence of the adamantane derivative of Ademol on DNA-fragmentation in the nuclei of neurons in the frontal lobes of the cortex during ischemia-reperfusion brain in rats. [Doslidzhennya vplivu pohidnogo adamantanu ademolu na fragmentatsiyu DNK yader neyroniv lobnih chastok kori za ishemiyi-reperfuziyi golovnogo mozku u shchuriv]. Ukrains’kyi Visnyk Psykhonevrolohii - The Ukrainian bulletin of psychoneurology, 2013. Vol. 21, no. 1(74). Pp. 26-28.
12. Shvedskiy V.V., Shtrigol S.Yu., Hodakivskiy O.A. Modern cerebroprotective therapy of acute cerebral circulatory disorders under diabetes and ways of its optimization. [Suchasna tserebroprotektorna terapiya gostrih porushen mozkovogo krovoobigu pri tsukrovomu diabeti ta shlyahi yiyi optimizatsiyi]. Klinichna farmatsiya- Clinical pharmacy, 2011. Vol. 15, no. 2. Pp. 7-12.
13. Iavorskaia V.A., Flomin Iu.V., Grebeniuk A.V. Citicoline in acute stroke: mechanisms of action, safety and efficacy (scientific review). [Tsitikolin pri ostrom insul'te: mekhanizm deistviia, bezopasnost' i effektivnost' (nauchnyi obzor)]. Mezhdunarodnyi nevrologicheskii zhurnal–International Journal of neurology, 2011. No. 2 (40). Pp. 74-80.
14. Davalos A., Alvarez-Sabin J., Castillo J. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet, 2012. 380. Рp. 349-357